Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
L
LBRX
vs
S&P 500
S&P 500
Over the past 12 months, LBRX has significantly outperformed S&P 500, delivering a return of +128% compared to S&P 500's +16% growth.
Stocks Performance
LBRX vs S&P 500
Performance Gap
LBRX vs S&P 500
Performance By Year
LBRX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
LB Pharmaceuticals Inc
Glance View
LB Pharmaceuticals is a biopharmaceutical company that develops prescription medicines, likely focused on nervous-system or mental-health disorders. It is not a consumer drug company with a shelf product line; instead, it builds drug candidates in the lab, runs clinical trials, and works toward regulatory approval. Its business starts with research and ends, if things go well, with approved therapies that doctors can prescribe to patients. The company’s main customers are not end users today but the healthcare system it hopes to serve later: physicians, hospitals, pharmacies, and patients who need its medicines. Before a drug is approved, LB Pharmaceuticals can also earn money through research partnerships, licensing deals, and milestone payments from larger pharmaceutical collaborators. If its medicines reach the market, most of the long-term revenue would come from product sales or royalties. What makes this business model different is that the company’s value depends heavily on scientific results, patent protection, and regulatory approval rather than manufacturing scale or a broad product catalog. Each drug program is a focused bet: if trials succeed, the company can create a valuable new treatment; if they fail, the program may be written off. That makes LB Pharmaceuticals more like a pipeline-based drug developer than a traditional operating company.